
The findings of the team led by Prof. Melanie Schirmer provide starting points for new therapies for advanced chronic liver disease.
Photo Credit: Astrid Eckert / TUM
Scientific Frontline: "At a Glance" Summary
- Main Discovery: Specific oral bacteria were found to translocate to and colonize the gut in patients with chronic liver disease, where they actively contribute to disease progression rather than acting as passive bystanders.
- Mechanism of Action: These translocated bacteria express genes encoding collagen-degradation enzymes (collagenases) that damage the intestinal barrier, allowing bacterial pathogens to leak into the liver and exacerbate fibrosis.
- Methodology: The study combined comparative microbiome sequencing of patient samples with in vivo mouse experiments, demonstrating that introducing these specific oral strains into mice directly worsened gut barrier damage and liver condition.
- Key Observation: While healthy individuals maintain distinct oral and gut microbiomes, patients with advanced liver disease exhibited nearly identical bacterial strains in both sites, indicating significant bacterial migration.
- Diagnostic Application: The presence and abundance of the specific gene responsible for collagen degradation in stool samples were identified as a reliable biomarker for distinguishing patients with liver disease from healthy individuals.
- Therapeutic Potential: These findings suggest that therapies targeting the oral microbiome or inhibiting microbial collagenase activity could restore gut barrier integrity and slow the progression of chronic liver disease.


.jpg)


.jpg)
.jpg)
